IDiyas

For the Inventor, By the Inventor

Belmont, MA, United States of America

Martin C Wright

USPTO Granted Patents = 22 

 

Average Co-Inventor Count = 6.0

ph-index = 13

Forward Citations = 510(Granted Patents)


Location History:

  • Cambridge, MA (US) (2003 - 2005)
  • Boston, MA (US) (2010 - 2016)
  • Belmont, MA (US) (2015 - 2022)

Company Filing History:

goldMedal19 out of 3,681 
 
Bristol-myers Squibb Compnay
 patents
silverMedal2 out of 10 
 
Phylos, Inc.
 patents
where one patent can have more than one assignee

Years Active: 2003-2025

Loading Chart...
Loading Chart...
22 patents (USPTO):Explore Patents
1. 12198515 - Light switch systems configured to respond to gunfire and methods of use (2025-01-14),
2. 12194110 - PD-L1 binding polypeptides for imaging (2025-01-14),
3. 11344639 - PET imaging with PD-L1 binding polypeptides (2022-05-31),
4. 11173219 - PD-L1 binding polypeptides for imaging (2021-11-16),
5. 11149077 - Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR (2021-10-19),
6. 10995131 - Libraries of modified fibronectin type III tenth domain-containing polypeptides (2021-05-04),
7. 10954286 - Bispecific EGFR/IGFIR binding molecules (2021-03-23),
8. 10406251 - PD-L1 binding polypeptides for imaging (2019-09-10),
9. 10221232 - Methods of treating cancer by administering IGF-IR binding molecules (2019-03-05),
10. 10183987 - Polynucleotides encoding bispecific EGFR/IGF-IR binding molecules (2019-01-22),
11. 9862758 - Inhibitors of type 2 vascular endothelial growth factor receptors (2018-01-09),
12. 9771411 - Method of treating cancer by administering EGFR and EGFR/IGFIR binding molecules (2017-09-26),
13. 9328157 - Inhibitors of type 2 vascular endothelial growth factor receptors (2016-05-03),
14. 9017655 - Bispecific EGFR/IGFIR binding molecules (2015-04-28),
15. 8609613 - Methods of inhibiting type 2 vascular endothelial growth factor receptors using polypeptides (2013-12-17),

Title: Exploring the Innovations of Martin C. Wright

Introduction: Martin C. Wright, based in Belmont, MA, is a prominent inventor with an impressive portfolio of 19 patents. His work primarily focuses on advancements in the field of imaging agents and diagnostics, contributing significantly to the medical research landscape.

Latest Patents: Among his noteworthy innovations, Martin has recently developed patents related to PD-L1 binding polypeptides for imaging. These include novel Fn3 domains that specifically bind to PD-L1, which are crucial for diagnostics. Another significant patent involves PET imaging with PD-L1 binding polypeptides, showcasing his commitment to enhancing diagnostic techniques in the medical field.

Career Highlights: Martin is currently associated with Bristol-Myers Squibb Company, where his innovative work continues to shape the future of medical diagnostics. His substantial contributions have established him as a key figure in his area of expertise, highlighting his importance in the development of critical diagnostic tools.

Collaborations: In his journey of innovation, Martin has collaborated with several professionals, including Jochem Gokemeijer and Ray Camphausen. These partnerships reflect a team-oriented approach to research, fostering an environment of shared knowledge and expertise.

Conclusion: Martin C. Wright's contributions to innovation in imaging and diagnostics are noteworthy. With a robust record of patents and collaborations, he exemplifies the spirit of invention that drives progress in the medical field. His work not only enhances our understanding of diagnostics but also improves the potential for future developments in healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…